ZA957891B - Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence - Google Patents

Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence

Info

Publication number
ZA957891B
ZA957891B ZA957891A ZA957891A ZA957891B ZA 957891 B ZA957891 B ZA 957891B ZA 957891 A ZA957891 A ZA 957891A ZA 957891 A ZA957891 A ZA 957891A ZA 957891 B ZA957891 B ZA 957891B
Authority
ZA
South Africa
Prior art keywords
serotonin reuptake
reuptake inhibitor
antagonist
selective serotonin
alcoholosm
Prior art date
Application number
ZA957891A
Other languages
English (en)
Inventor
Leonard Cook
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of ZA957891B publication Critical patent/ZA957891B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA957891A 1994-09-19 1995-09-19 Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence ZA957891B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19

Publications (1)

Publication Number Publication Date
ZA957891B true ZA957891B (en) 1997-03-19

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA957891A ZA957891B (en) 1994-09-19 1995-09-19 Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence

Country Status (11)

Country Link
US (1) US5958962A (de)
EP (1) EP0782445B1 (de)
AT (1) ATE214276T1 (de)
AU (1) AU3419995A (de)
CA (1) CA2197554A1 (de)
CO (1) CO4410317A1 (de)
DE (1) DE69525847T2 (de)
DK (1) DK0782445T3 (de)
HR (1) HRP950485A2 (de)
WO (1) WO1996009047A1 (de)
ZA (1) ZA957891B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
DK0980241T3 (da) * 1997-07-01 2004-04-05 Pfizer Prod Inc Gelatineindkapslede opløsningsdosisformer af sertralin
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
WO2001032178A1 (en) * 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
EP2092936B1 (de) 2000-02-08 2013-03-20 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
RU2004107501A (ru) * 2001-08-14 2005-02-20 Байотай Терапис Корпорейшн (Fi) Способ лечения алкоголизма или злоупотребления алкоголем
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
EP3173082A1 (de) * 2002-05-17 2017-05-31 Duke University Verfahren zur behandlung von adipositas
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1617832B1 (de) * 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Zusammensetzungen zur beeinflussung des gewichtsverlusts
EP1870096A3 (de) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Zusammensetzungen zur Beeinflussung von Gewichtsverlust
US20040253642A1 (en) * 2003-06-06 2004-12-16 Grant Zimmermann System and method for multidimensional evaluation of combinations of compositions
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
KR20060128995A (ko) 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (de) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Verfahren zur behandlung von angstzuständen
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3946547B1 (de) 2019-03-26 2026-03-25 Pinova Therapeutics Inc. Vorrichtungen und verfahren zur abgabe von pharmazeutischen zusammensetzungen
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
JPH06507416A (ja) * 1991-05-07 1994-08-25 ダイナジェン・インコーポレーテッド 禁煙のための調節された持続的放出伝達システム
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
CO4410317A1 (es) 1997-01-09
WO1996009047A1 (en) 1996-03-28
ATE214276T1 (de) 2002-03-15
HRP950485A2 (en) 1997-08-31
US5958962A (en) 1999-09-28
DK0782445T3 (da) 2002-05-06
EP0782445A1 (de) 1997-07-09
AU3419995A (en) 1996-04-09
DE69525847D1 (de) 2002-04-18
DE69525847T2 (de) 2002-09-05
EP0782445B1 (de) 2002-03-13
CA2197554A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
ZA957891B (en) Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
BG101446A (bg) Антинеопластични какаови екстракти, метод за получаване и използване
FI965203A7 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
WO2000002549A3 (en) Composition for and method of treating neurological disorders
PL343069A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
EP1262196A3 (de) Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
FI954245A7 (fi) Koostumuksia ja menetelmiä immunovälitteisten tulehduksellisten häiriö iden hoitamiseksi
ZA949564B (en) Method for treating constipation using dimeticone.
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
WO1998041238A3 (en) Methods and kits for treating and diagnosing leiomyomas
IL118491A0 (en) Use of pyrrolidine derivatives in the treatment of alcoholism
RO118794B1 (ro) Metodă de tratament a unor stări dependente de steroizii gonadici
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
AU9294698A (en) Methods and compositions for enhanced wound healing
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
IL129267A0 (en) Treatment of urinary incontinence and compositions for use therein
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
EP0954321A4 (de) Synergistische, gold enthaltende zusammensetzungen.
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.
ES2119581A1 (es) Utilizacion de fragmentos de timosina y/o sus derivados